ArticleProbiotics and antimicrobial proteins2023
Assessment of Two Potential Probiotic Strains As Anti-Obesity Supplements Under High-Fat Feeding Conditions.
Article in Probiotics and antimicrobial proteins, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- Mitigating Cadmium Toxicity: The Therapeutic Potential of Lactobacillus acidophilus Pro4 in Mice.Probiotics and antimicrobial proteins · 2026Article
- Harnessing the Power of Probiotics: Boosting Immunity and Safeguarding against Various Diseases and Infections.Recent advances in anti-infective drug discovery · 2025Review
- Anti-inflammatory and Immunomodulatory Potency of Selenium-Enriched Probiotic Mutants in Mice with Induced Ulcerative Colitis.Biological trace element research · 2023Article
- Evaluation of the effectiveness of two new strains of Lactobacillus on obesity-induced kidney diseases in BALB/c mice.Journal, genetic engineering & biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is one of the chronic diseases that increase annually and cause cardiovascular disease, which is the main cause of death worldwide. So, this study aims to evaluate the role of the two potential probiotics: Lactiplantibacillus plantarum Pro1 and Lacticaseibacillus rhamnosus Pro2, isolated from the fermented milk and corn silage as anti-obesity supplements. Seventy-five male BALB/c mice were distributed to five groups (control, obesity, obesity plus L. plantarum (OLP), obesity plus L. rhamnosus (OLR) and obesity plus mixture of two strains (OM)). The body weight, lipid profile, histopathology and enzymes of liver were assessed. RT-PCR was used to determine the expression of CYP7A1, ALTG4, TNFα and ROR genes.The findings show that the obesity group recorded the significant highest value of the body weight, TC, TG, LDL, AST and ALT, while OLP group recorded the significant lowest value. Liver tissue of obesity group has necrosis and fatty changes, while the OLP group was related to the control group. The findings of RT-PCR show non-significant differences between the control group and the OLP group, with significant differences between the control group and the set groups in expression of CYP7A1, ALTG4, TNFα and ROR genes. L. plantarum Pro1 reduced the expression of inflammation genes (TNFα and ROR), and increase the expression of the lipid metabolism genes (CYP7A1, ALTG4) to reduce the inflammatory effects of obesity in the liver, and decrease the cholesterol level in serum. Therefore, L. plantarum Pro1 is useful as anti-obesity supplements and an eliminator of the relevant diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.